Overview
David Armisen practices practicing medicine in Lyon, France.
His clinical expertise encompasses Chronic T-Cell Leukemia (CTCL) and Prolymphocytic Leukemia.
He is actively involved in clinical research, co-authoring 24 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about David Armisen
Is David Armisen a top-rated expert for Chronic T-Cell Leukemia (CTCL)?
MediFind is an objective health platform that identifies experts based on real-world data. David Armisen is classified as an Experienced expert for Chronic T-Cell Leukemia (CTCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does David Armisen participate in research or clinical trials?
Yes. David Armisen has published 24 articles and abstracts on conditions like Chronic T-Cell Leukemia (CTCL). You can view a list of David Armisen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Chronic T-Cell Leukemia (CTCL)Mr. Armisen isExperienced. Learn about Chronic T-Cell Leukemia (CTCL).
- Prolymphocytic LeukemiaMr. Armisen isExperienced. Learn about Prolymphocytic Leukemia.